No Data
yabao pharmaceutical group's two children's medicines revenue increased year-on-year, hydrochloride betahistine injection has not stopped the decline in revenue|direct hit earnings conference
yabao pharmaceutical group stated at the earnings conference that in the first three quarters of this year, the company's pediatric products revenue increased year-on-year. The company's secretary stated that while the revenue of levocetirizine hydrochloride injection decreased, the sales volume increased, and predicted that the 'income decline in the category will continue to narrow within the year'. yabao pharmaceutical group also provided explanations on the company's research pipeline progress, share buybacks, and other situations.
Yabao Pharmaceutical Group Co., Ltd. Report for the Third Quarter of 2024 (Revised Edition)
Yabao Pharmaceutical Group Co., Ltd. 2024 Third Quarter Report Correction Notice
Yabao Pharmaceutical Group Co., Ltd. Report for the Third Quarter of 2024
yabao pharmaceutical group (600351.SH) released its performance for the first three quarters, with a net income of 0.235 billion yuan, a year-on-year increase of 9.88%
yabao pharmaceutical group (600351.SH) disclosed the third quarter report for 2024, achieving revenue of 21...
Yabao Pharmaceutical Group (600351.SH): The net income for the first three quarters was 0.235 billion yuan, a year-on-year increase of 9.88%.
Gelonghui October 24th | Yabao Pharmaceutical Group (600351.SH) announced its third quarter report for the year 2024, with the company's revenue for the first three quarters at 2.122 billion yuan, a 3.54% year-on-year decrease; the net income attributable to the shareholders of the listed company was 0.235 billion yuan, a 9.88% year-on-year increase; and the basic earnings per share was 0.3241 yuan.
The Market Doesn't Like What It Sees From Yabao Pharmaceutical Group Co., Ltd's (SHSE:600351) Earnings Yet As Shares Tumble 27%No Data
No Data
